论文部分内容阅读
阿西替尼(axitinib)是由美国Pfizer公司研发的一种多靶点酪氨酸激酶抑制剂。于2012年1月27日获美国FDA批准上市,商品名为Inlyta。该药为片剂,用于治疗对药物没有应答的晚期肾癌(肾细胞癌)。阿西替尼的中文化学名称:N-甲基-2-((3-((1E)-2-(吡啶-2-基)乙烯)-
Axitinib (axitinib) is a multi-target tyrosine kinase inhibitor developed by the United States Pfizer company. January 27, 2012 by the US FDA approved the listing, the trade name is Inlyta. This medicine is a tablet for the treatment of advanced renal cell carcinoma (renal cell carcinoma) that is unresponsive to drugs. Chinese chemical name of axitinib: N- methyl-2 - ((3 - ((1E) -2- (pyridin- 2-yl) ethene)